Avemar film-coated tablet is a dietary supplement for cancer patients, containing Avemar pulvis – fermented wheat germ extract.
Indication: Avemar film-coated tablet is recommended to cancer patients to complement their clinical oncological treatments (surgery, radiotherapy, chemotherapy, immunotherapy etc.). Avemar can be used in cancer related cachexia. Avemar film-coated tablet may be taken without interruption before, during and after oncological treatments. Avemar film-coated tablet may be taken during any stage of malignant disease.
After surgery, Avemar film-coated tablet may be initiated when the patient is able to take oral food without complications for at least 4 days.
Side effects: Soft stool, unsettled stomach and nausea are very infrequent side effects of Avemar film-coated tablet.
Contraindications: Women who are pregnant or nursing should not consume the product. Avemar is also strictly contraindicated for patients undergoing organ or tissue transplantations. Avemar film-coated tablet should not be consumed by patients suffering from malabsorption syndrome (serious impairment of absorption). The product is contraindicated in gluten sensitive enteropathies (celiac sprue) or for patients with hypersensitivity to any of the components or ingredients of the product.
Known interactions: Avemar film-coated tablet may be consumed 2 hours before or after taking preparations with vitamin C content. It is recommended to take Avemar and other supplements or drugs at different times.
Use: It is recommended to take half of the daily dose in the morning and the other half in the evening. 10 tablets of Avemar are equal to one sachet (17g) of Avemar granulate.
- For adults with body weight less than 50 kg: 8 tablets
(4 tablets twice a day)
- For adults with body weight between 50-90 kg: 10 tablets
(5 tablets twice a day)
- For adults with body weight above 90 kg: 14 tablets
(7 tablets twice a day)
Important notice: Avemar film-coated tablet is not intended to substitute cancer therapies or drugs.
Not recommended for children under the age of 14. Keep out of reach of children.
Must be used under medical supervision.
Avemar film-coated tablet is not suitable for use as the sole source of nourishment. Avemar should not be used parenterally.
In case of examinations in which oral contrast material is used, the instructions of the doctor should be respected.
Storage requirements: Avemar tablet should be stored in conditions below 22˚C degrees. A refrigerated environment is a suggested option. Avemar tablet is easier to store, transport and dose than Avemar granulate. 150 tablets are sufficient for 11-18 days depending on the bodyweight.
Packaging units available: 2 bottles/box (300 tablets)
Ingredients: Avemar pulvis concentrate (from this standardized fermented wheat germ extract 75 %, maltodextrin, anti-caking agent [silicon dioxide]), maize starch, microcrystalline cellulose, emulsifiers [(hydroxil-propyl-methyl)-cellulose, (hydroxy-propyl)-cellulose)], anti-caking agents (silicon-dioxide, magnesium salt of fatty-acid, talc), colours (titan-dioxide, in very negible proportion: tartrazine yellow*, sunset yellow*, indigo-carmine*)
*Potentially harmful to the activity and attention span of children. It does not contain added sugar or sweetener.
1. What is the Avemar film-coated tablet?
The Avemar film-coated tablet is a dietary food for special medical purposes, for the supplementation of treatment of cancer patients.
2. What is the active ingredient of Avemar?
The Avemar pulvis concentrate is a special, patented extract produced by pharmaceutical technology. Wheat germ is only the basic raw material of Avemar pulvis. Ten Avemar film-coated tablets contain 7.4 g of Avemar pulvis concentrate. Ten Avemar film-coated tablets are equal to 1 packet (17 g) of conventional Avemar microgranulate.
3. Does the Avemar film-coated tablet contain added sugar, sweetener or aroma?
No, it does not.
4. In which cases is it recommended to take the Avemar film-coated tablet?
The Avemar film-coated tablet is suggested for the supplementation of the clinical oncological treatments (surgery, radiotherapy, chemotherapy, immunotherapy, etc.) of cancer patients. The Avemar film-coated tablet is recommended to be taken without interruption before, during the full course and after the completion of oncological treatments. Avemar film-coated tablet may be taken during any stage of a malignant disease. After surgery, the Avemar film-coated tablet can be initiated when the patient is able to take oral food without complications for at least 4 days.
5. When can the consumption of the Avemar film-coated tablet be initiated?
It is recommended to start taking Avemar right after the recognition of a malignant disease (diagnoses). There is no need to wait for the start of the oncological treatments.
6. What should be known before taking Avemar?
The product is not suitable for use as the sole source of nourishment. Avemar is not a replacement or a substitute for any oncological treatments or drugs!
7. How should the Avemar film-coated tablet be taken?
It is recommended to take Avemar continuously, without interruption. Following the completion of oncological treatments, it is also recommended to take the product for several years until the patient completely recovers. If the continuous taking of Avemar is interrupted or suspended for any reason, that can be restarted later again.
8. When must not the product be taken?
The product is contraindicated during pregnancy and breastfeeding. Avemar is also strictly contraindicated for patients undergoing organ or tissue transplantation.
This product must not be consumed by patients suffering from bleeding erosions and/or ulcers of the gastrointestinal tract (stomach and duodenal ulcers), enteritis/colitis (severe inflammations of the gastrointestinal tract) or Malabsorption Syndrome (serious impairment of absorption). The product is contraindicated in gluten sensitive enteropathies (celiac sprue) and for patients with hypersensitivity to any of the components of the product.
9. In which cases should the application of the Avemar film-coated tablet be temporarily suspended?
It is advised to suspend the application of the Avemar at least two days before a planned gastroenteral diagnostic procedure, in which oral administration of contrast material (such as barium sulfate) to the intestinal tract will be used. The consumption of may be continued the day after the procedure. In every case, the instructions of the therapist should be respected. In the case of examinations or procedures should be carried out on an empty stomach that must be taken into consideration relating to the consumption of Avemar also.
10. Can children take Avemar?
Avemar is not recommended for children younger than 14 years of age.
11. What unwanted effects may Avemar have?
Avemar may very infrequently have side effects, such as soft stool, unsettled stomach and nausea.
12. Can Avemar be taken together with other drugs, preparations?
Yes, it can. The Avemar should only be taken either 2 hours before or after the consumption of vitamin-C or any product containing vitamin C. It is highly recommended to take the Avemar film-coated tablet at a different time from other supplements or drugs.
13. What is the recommended daily dose and when should it be taken?
Body weight less than 50 kg: 4 film-coated tablets twice daily
Body weight of 50-90 kg: 5 film-coated tablets twice daily
Body weight above 90 kg: 7 film-coated tablets twice daily
It is recommended to take the half of the daily dosage in the morning and the other half of that in the evening.
14. How should Avemar film-coated tablet be stored and transported?
The product should be stored protecting from heat, at room temperature (max 22oC). If the temperature is above 22oC, then the product should be stored in refrigerator. Keep out of reach of children! Special caution should be taken to protect the product from any long-lasting extreme heat effect during its transportation.
15. Are the Avemar film-coated tablet and the well-known Avemar microgarnulate in packets produced by the same manufacturer?
Yes, both products are manufactured by Biropharma Ltd. In case of both products, the active ingredient, Avemar pulvis, is made by the same technology using the same ingredients.
16. What kind of scientific studies have been carried out with Avemar?
Please, visit the website www.avemar.com, where you will find a summary of all the prestigious Hungarian and international publications that cover the results and experiences of the clinical studies carried out with Avemar.
Packaging units: 2 bottles, each of 150 tablets
Net weight: 312 g (300 film-coated tablets)